AUTHORS
Joshua SW Yi, MSc, Lee Mozessohn, MD2, Maria Santiago3, Ning Liu, PhD4, Versha Banerji, MD5, Alina S. Gerrie, MD, FRCPC, MPH6, Robert Puckrin, MD7, Abi Vijenthira, MD, MS8
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 ICES, Toronto, Ontario, Canada, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
3 ICES, Toronto, Ontario, Canada
4 ICES, Toronto, Ontario, Canada, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
5 Paul Albrechtsen Research Institute CancerCare Manitoba, Winnipeg, Manitoba, Canada, University of Manitoba, Winnipeg, Manitoba, Canada
6 British Columbia Cancer Agency, Vancouver, British Columbia, Canada, Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver, British Columbia, Canada, University of British Columbia, Vancouver, British Columbia, Canada
7 Arthur Child Comprehensive Cancer Centre, Calgary, Alberta, Canada, University of Calgary, Calgary, Alberta, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
ABSTRACT
Background: Chronic lymphocytic leukemia (CLL) primarily affects older adults, although approximately 10% of patients are diagnosed at age 55 years or younger (a threshold commonly used in literature to define younger patients in this population). A scoping review conducted by our group identified limited published data on their specific outcomes, especially in the targeted therapy era.
Methods: The Canadian CLL Research Group (CanCLL) conducted a population-based propensity-matched cohort study of all patients diagnosed with CLL at age ≤55 years old in Ontario, Canada between January 2007 and December 2024. Patients with cancer within five years before index date were excluded. Patients were matched 1:4 to controls by age (within 1 year), sex, and a propensity score (≤0.2 standard deviations) which included comorbid disease burden, income quintile, rurality, and healthcare use. The primary outcome was all-cause mortality, and secondary outcomes included second primary malignancies (SPMs) and severe infections (requiring an emergency department visit or hospitalization). Subgroup analyses were performed according to age. A separate matched analysis was conducted on patients receiving frontline treatment after 2018 (when frontline BTK inhibitors (BTKi) were funded). Survival probability and effect sizes were estimated using Kaplan-Meier method and Cox regression. Cumulative incidence functions were used to estimate SPM and infection probabilities, with death as a competing risk.
Results: The cohort included 2,462 younger patients with CLL and 9,848 matched controls. Median age at diagnosis was 51 years (IQR, 46–53), 35.9% were female, and median follow-up was 9.2 years (IQR, 5.2–13.3). There were 1,213 patients (49.3%) aged ≤50 years and 232 (9.4%) aged ≤40 years. There were 824 patients (33.5%) diagnosed in 2007–2012, 928 (37.7%) in 2013–2018, and 710 (28.8%) in 2019–2024.
The 10-year survival estimate was significantly lower in patients with CLL compared to matched controls (86.6% [95% CI 84.9–88.2] vs. 96.0% [95% CI 95.5–96.4]; HR: 3.2 [95% CI 2.8–3.7]). The relative mortality hazard increased in younger age subgroups: ≤50 years (HR: 4.1, 95% CI 3.2–5.1); ≤40 years (HR: 6.2, 95% CI 3.0–13.0).
The SPM incidence rate of younger patients with CLL (12.8/1000 person-years (PY), 95% CI 11.2–14.4) was approximately 2-fold (HR: 1.9, 95% CI 1.6–2.2) compared to matched controls (6.37/1000-PY, 95% CI 5.85–6.95). The association was unchanged after excluding non-melanoma skin cancers (HR 1.9, 95% CI 1.6–2.2). Patients with CLL also had a higher rate of infection-related emergency department visits or hospitalizations compared to matched controls (53.6/1000-PY [95% CI 50.1–57.4] vs. 22.7/1000-PY [95% CI 21.5–23.9]; HR: 2.3 [95% CI 2.1–2.4]).
In the treatment cohort, 540 patients (21.9%) received treatment by age 55 years, with a median time-to-first treatment of 3.0 years (IQR 0.8–6.1). Median duration of follow up was 6.81 years (IQR 3.4–10.3). The 5-year survival estimate from treatment initiation was significantly lower in patients compared to matched controls (84.7% [95% CI 80.9–87.8] vs. 97.3% [95% CI 96.4–97.9]; HR: 5.1 [95% CI 3.9–6.7])). Of frontline treated patients, 336 (62.2%) received fludarabine-cyclophosphamide-rituximab (FCR), 166 (30.7%) received BTKi, and 38 (7.0%) received venetoclax-obinutuzumab (VO). Five-year survival was 84.7% (95% CI 80.3–88.2) with FCR and 83.4% (95% CI 73.9–89.7) with BTKi. Compared with their respective matched controls, mortality was higher in both groups (FCR: HR 4.7 [95% CI 3.4–6.3]; BTKi: HR 9.5 [95% CI 4.7–19.4]). Although IGHV status was unavailable at time of analysis, the BTKi cohort was enriched for patients with unmutated IGHV or TP53 aberrations due to provincial funding criteria. Patients receiving VO had 1-year survival of 100.0% (HR could not be reliably estimated).
Conclusions: Younger patients with CLL experience substantially higher risks for all-cause mortality, SPMs, and severe infections compared to matched controls. Despite the availability of targeted therapies since 2018, survival of younger patients undergoing treatment remains significantly worse than matched controls. Further research is required to determine the long-term benefit of targeted therapies and inform cancer surveillance and prophylaxis strategies for this younger patient population.
DISCLOSURES
Joshua SW Yi, MSc: No relevant conflicts of interest to declare.